{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:59:23Z","timestamp":1792173563352,"version":"4.4.0"},"reference-count":49,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"abstract":"<jats:p>Ebola disease (EBOD) remains a significant and ongoing threat to African countries, characterized by a mortality rate of 25% to 90% in patients with high viral load and significant transmissibility. The most recent outbreak, reported in Uganda in September 2022, was declared officially over in January 2023. However, it was caused by the Sudan Ebola virus (SUDV), a culprit species not previously reported for a decade. Since its discovery in 1976, the management of EBOD has primarily relied on supportive care. Following the devastating outbreak in West Africa from 2014 to 2016 secondary to the Zaire Ebola virus (EBOV), where over 28,000 lives were lost, dedicated efforts to find effective therapeutic agents have resulted in considerable progress in treating and preventing disease secondary to EBOV. Notably, 2 monoclonal antibodies\u2014Ebanga and a cocktail of monoclonal antibodies, called Inmazeb\u2014received Food and Drug Administration (FDA) approval in 2020. Additionally, multiple vaccines have been approved for EBOD prevention by various regulatory bodies, with Ervebo, a recombinant vesicular stomatitis virus-vectored vaccine against EBOV being the first vaccine to receive approval by the FDA in 2019. This review covers the key signs and symptoms of EBOD, its modes of transmission, and the principles guiding supportive care. Furthermore, it explores recent advancements in treating and preventing EBOD, highlighting the unique properties of each therapeutic agent and the ongoing progress in discovering new treatments.<\/jats:p>","DOI":"10.1371\/journal.ppat.1012038","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T13:29:17Z","timestamp":1710509357000},"page":"e1012038","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":49,"title":["Recent advances in the treatment of Ebola disease: A brief overview"],"prefix":"10.1371","volume":"20","author":[{"given":"L\u2019Emir Wassim","family":"El Ayoubi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnny","family":"Zakhour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6413-3396","authenticated-orcid":true,"given":"Souha S.","family":"Kanj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,3,15]]},"reference":[{"issue":"1","key":"ppat.1012038.ref001","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-020-0147-3","article-title":"Ebola virus disease (Primer).","volume":"6","author":"ST Jacob","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"ppat.1012038.ref002","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3390\/v14030579","article-title":"Therapeutic strategies against ebola virus infection.","volume":"14","author":"C-H Liu","year":"2022","journal-title":"Viruses."},{"key":"ppat.1012038.ref003","author":"Center for Disease Control and Prevention","year":"2023","journal-title":"History of Ebola Disease Outbreaks"},{"issue":"5","key":"ppat.1012038.ref004","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41579-019-0187-4","article-title":"New filovirus disease classification and nomenclature","volume":"17","author":"JH Kuhn","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"ppat.1012038.ref005","year":"2023","journal-title":"Center for Disease Control and PreventionEbola Virus Disease Treatment"},{"issue":"10121","key":"ppat.1012038.ref006","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(17)31795-6","article-title":"Evidence-based guidelines for supportive care of patients with Ebola virus disease","volume":"391","author":"F Lamontagne","year":"2018","journal-title":"Lancet"},{"issue":"9","key":"ppat.1012038.ref007","first-page":"442","article-title":"Ebola virus disease: a review on epidemiology, symptoms, treatment and pathogenesis.","volume":"72","author":"M Goeijenbier","year":"2014","journal-title":"Neth J Med"},{"key":"ppat.1012038.ref008","first-page":"349","article-title":"Ebola virus disease","author":"NJ Beeching","year":"2014","journal-title":"BMJ"},{"issue":"24","key":"ppat.1012038.ref009","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"S Mulangu","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"ppat.1012038.ref010","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1513\/AnnalsATS.201410-481PS","article-title":"Clinical presentation and management of severe Ebola virus disease.","volume":"11","author":"TE West","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"ppat.1012038.ref011","author":"World Health Organization","year":"2018","journal-title":"Preferred Product Characteristics for Personal Protective Equipment for the Health Worker on the Frontline Responding to Viral Hemorrhagic Fevers in Tropical Climates."},{"key":"ppat.1012038.ref012","author":"World Health Organization","year":"2019","journal-title":"Optimized supportive care for Ebola virus disease: clinical management standard operating procedures."},{"issue":"7","key":"ppat.1012038.ref013","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1056\/NEJMoa1504874","article-title":"Clinical management of Ebola virus disease in the United States and Europe","volume":"374","author":"TM Uyeki","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"ppat.1012038.ref014","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/S1473-3099(15)00137-1","article-title":"Clinical features of patients isolated for suspected Ebola virus disease at Connaught Hospital, Freetown, Sierra Leone: a retrospective cohort study","volume":"15","author":"M Lado","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"ppat.1012038.ref015","doi-asserted-by":"crossref","first-page":"e0201091","DOI":"10.1371\/journal.pone.0201091","article-title":"Barriers to supportive care during the Ebola virus disease outbreak in West Africa: Results of a qualitative study.","volume":"13","author":"C Loignon","year":"2018","journal-title":"PLoS ONE."},{"issue":"10","key":"ppat.1012038.ref016","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/S1473-3099(22)00607-7","article-title":"New guidelines for treatment of Ebola virus disease","volume":"22","author":"T. Burki","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"ppat.1012038.ref017","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jinf.2015.03.004","article-title":"Bacterial co-infection is rare in patients with Ebola virus disease in a military Ebola virus disease treatment unit in Sierra Leone.","volume":"71","author":"L Lamb","year":"2015","journal-title":"J Infect"},{"issue":"25","key":"ppat.1012038.ref018","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa1411677","article-title":"A case of severe Ebola virus infection complicated by gram-negative septicemia","volume":"371","author":"B Kreuels","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"ppat.1012038.ref019","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1056\/NEJMoa1411249","article-title":"Clinical presentation of patients with Ebola virus disease in Conakry, Guinea","volume":"372","author":"EI Bah","year":"2015","journal-title":"N Engl J Med"},{"key":"ppat.1012038.ref020","volume-title":"Open Forum Infectious Diseases","author":"MJ Matson","year":"2019"},{"key":"ppat.1012038.ref021","author":"World Health Organization","year":"2019","journal-title":"Optimized supportive care for Ebola virus disease: clinical management standard operating procedures"},{"key":"ppat.1012038.ref022","doi-asserted-by":"crossref","first-page":"721328","DOI":"10.3389\/fimmu.2021.721328","article-title":"insights on current FDA-approved monoclonal antibodies against ebola virus infection","volume":"12","author":"O Tshiani Mbaya","year":"2021","journal-title":"Front Immunol"},{"issue":"15","key":"ppat.1012038.ref023","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1604330","article-title":"A randomized, controlled trial of ZMapp for Ebola virus infection","volume":"375","author":"PIW Group","year":"2016","journal-title":"N Engl J Med"},{"key":"ppat.1012038.ref024","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.antiviral.2015.10.010","article-title":"The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virus","volume":"125","author":"LK McMullan","year":"2016","journal-title":"Antiviral Res"},{"issue":"9","key":"ppat.1012038.ref025","doi-asserted-by":"crossref","first-page":"e0162199","DOI":"10.1371\/journal.pone.0162199","article-title":"Experimental Treatment of Ebola Virus Disease with Brincidofovir.","volume":"11","author":"J Dunning","year":"2016","journal-title":"PLoS ONE."},{"issue":"7496","key":"ppat.1012038.ref026","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature13027","article-title":"Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430","volume":"508","author":"TK Warren","year":"2014","journal-title":"Nature"},{"issue":"4","key":"ppat.1012038.ref027","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/cpdd.1037","article-title":"Pharmacokinetics and Safety of the Nucleoside Analog Antiviral Drug Galidesivir Administered to Healthy Adult Subjects","volume":"11","author":"A Mathis","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"4","key":"ppat.1012038.ref028","doi-asserted-by":"crossref","first-page":"e1001997","DOI":"10.1371\/journal.pmed.1001997","article-title":"Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial.","volume":"13","author":"J Dunning","year":"2016","journal-title":"PLoS Med."},{"issue":"4","key":"ppat.1012038.ref029","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/cid\/civ334","article-title":"The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States","volume":"61","author":"CS Kraft","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"1","key":"ppat.1012038.ref030","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa1511812","article-title":"Evaluation of convalescent plasma for Ebola virus disease in Guinea","volume":"374","author":"J Van Griensven","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"ppat.1012038.ref031","doi-asserted-by":"crossref","first-page":"e1010078","DOI":"10.1371\/journal.ppat.1010078","article-title":"Current state of Ebola virus vaccines: A snapshot.","volume":"17","author":"C Woolsey","year":"2021","journal-title":"PLoS Pathog"},{"key":"ppat.1012038.ref032","author":"World Health Organization","year":"2021","journal-title":"Meeting of the Strategic Advisory Group of Experts on Immunization"},{"issue":"26","key":"ppat.1012038.ref033","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2200072","article-title":"Randomized Trial of Vaccines for Zaire Ebola Virus Disease","volume":"387","author":"PS Team","year":"2022","journal-title":"N Engl J Med"},{"issue":"10068","key":"ppat.1012038.ref034","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!).","volume":"389","author":"AM Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"issue":"10","key":"ppat.1012038.ref035","doi-asserted-by":"crossref","first-page":"e1003813","DOI":"10.1371\/journal.pmed.1003813","article-title":"Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa.","volume":"18","author":"H Barry","year":"2021","journal-title":"PLoS Med"},{"key":"ppat.1012038.ref036","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ijid.2021.09.053","article-title":"Post-exposure prophylaxis following high-risk contact with Ebola virus, using immunotherapies with monoclonal antibodies, in the eastern Democratic Republic of the Congo: an emergency use program","volume":"113","author":"M Jaspard","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"11","key":"ppat.1012038.ref037","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1093\/cid\/ciz1165","article-title":"Postexposure prophylaxis with rVSV-ZEBOV following exposure to a patient with Ebola virus disease relapse in the United Kingdom: An operational, safety, and immunogenicity report","volume":"71","author":"C Davis","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"11","key":"ppat.1012038.ref038","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S1473-3099(15)00228-5","article-title":"Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents: a case-series of health-care workers","volume":"15","author":"M Jacobs","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"ppat.1012038.ref039","article-title":"Artificial Intelligence, Machine Learning, and Big Data for Ebola Virus Drug Discovery.","volume":"16","author":"SK Kwofie","year":"2023"},{"issue":"suppl_5","key":"ppat.1012038.ref040","doi-asserted-by":"crossref","first-page":"S592","DOI":"10.1093\/infdis\/jiy345","article-title":"In vitro and in vivo activity of amiodarone against Ebola virus","volume":"218","author":"J Dyall","year":"2018","journal-title":"J Infect Dis"},{"issue":"Suppl 2","key":"ppat.1012038.ref041","doi-asserted-by":"crossref","first-page":"S425","DOI":"10.1093\/infdis\/jiv223","article-title":"Novel Small Molecule Entry Inhibitors of Ebola Virus","volume":"212","author":"A Basu","year":"2015","journal-title":"J Infect Dis"},{"key":"ppat.1012038.ref042","doi-asserted-by":"crossref","first-page":"105011","DOI":"10.1016\/j.antiviral.2021.105011","article-title":"Identification of potential inhibitors of protein-protein interaction useful to fight against Ebola and other highly pathogenic viruses","volume":"186","author":"F Lasala","year":"2021","journal-title":"Antiviral Res"},{"issue":"6310","key":"ppat.1012038.ref043","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1126\/science.aag3267","article-title":"A \u201cTrojan horse\u201d bispecific-antibody strategy for broad protection against ebolaviruses.","volume":"354","author":"AZ Wec","year":"2016","journal-title":"Science"},{"issue":"4","key":"ppat.1012038.ref044","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1172\/JCI89857","article-title":"Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects","volume":"127","author":"E Bekerman","year":"2017","journal-title":"J Clin Invest"},{"issue":"1","key":"ppat.1012038.ref045","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.chom.2018.12.005","article-title":"A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates","volume":"25","author":"ZA Bornholdt","year":"2019","journal-title":"Cell Host Microbe"},{"key":"ppat.1012038.ref046","first-page":"7","article-title":"Combination therapy with remdesivir and monoclonal antibodies protects nonhuman primates against advanced Sudan virus disease","author":"RW Cross","year":"2022"},{"key":"ppat.1012038.ref047","author":"World Health Organization","year":"2022","journal-title":"Sudan Ebolavirus\u2013Experts deliberations. Candidate treatments prioritization and trial design discussions"},{"issue":"12","key":"ppat.1012038.ref048","doi-asserted-by":"crossref","first-page":"e1003065","DOI":"10.1371\/journal.ppat.1003065","article-title":"Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus.","volume":"8","author":"GS Mohan","year":"2012","journal-title":"PLoS Pathog.PubMed Central PMCID"},{"issue":"2","key":"ppat.1012038.ref049","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.chom.2023.01.002","article-title":"Structure of the Inmazeb cocktail and resistance to Ebola virus escape","volume":"31","author":"V Rayaprolu","year":"2023","journal-title":"Cell Host Microbe"}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1012038","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T13:29:46Z","timestamp":1710509386000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1012038"}},"subtitle":[],"editor":[{"given":"Wendy","family":"Maury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":49,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1012038","relation":{},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,15]]}}}